- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NVO
Recent news which mentions NVO
From Motley Fool
Is This Simple Index Fund a Millionaire Maker?
March 19, 2025
From Motley Fool
Is Novo Nordisk a No-Brainer Buy After It Dropped 40%?
March 19, 2025
From Motley Fool
UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension
March 17, 2025
From Benzinga
Why Hims & Hers Stock Popped on Monday
March 17, 2025
From Motley Fool
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
March 17, 2025
From Motley Fool
CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants
March 14, 2025
From Benzinga
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
March 14, 2025
From Benzinga
The Motley Fool's Market Volatility Toolkit
March 13, 2025
From Motley Fool
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
March 13, 2025
From Benzinga
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
March 12, 2025
From Motley Fool
Why Hims & Hers Health Stock Just Popped
March 11, 2025
From Motley Fool
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
March 11, 2025
From Benzinga
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
March 11, 2025
From Benzinga
From Motley Fool
From Motley Fool
The State of Weight Loss Drugs
March 10, 2025
From Motley Fool
3 Cold Stocks That Can Bounce Back This Week
March 10, 2025
From Motley Fool
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
March 10, 2025
From Benzinga
Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
March 06, 2025
From Benzinga
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
March 06, 2025
From Benzinga
From Motley Fool
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
March 05, 2025
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.